Cite
HARVARD Citation
Das, R. et al. (2022). A molecular perspective for the use of type IV tyrosine kinase inhibitors as anticancer therapeutics. Drug discovery today. 27 (3), pp. 808-821. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Das, R. et al. (2022). A molecular perspective for the use of type IV tyrosine kinase inhibitors as anticancer therapeutics. Drug discovery today. 27 (3), pp. 808-821. [Online].